文献速递甲状腺疾病

CHEK2奠基者变异与甲状腺癌风险

CHEK2 Founder Variants and Thyroid Cancer Risk.
PubMed 文献 · Thyroid · 2024-02-27

在三个非选择性非髓样甲状腺癌(NMTC)患者组中评估三种CHEK2奠基者变异与NMTC易感性的关联。c.444+1G>A仅见于1例;c.1100del和c.470T>C/p.I157T在各组的OR值95%CI均跨1,提示对甲状腺癌风险影响有限。

要点

  • 波兰常见变异c.444+1G>A在非选择性NMTC患者中仅见1例。
  • c.1100del与NMTC的OR在各组为1.71、2.64和2.5,95%CI均跨1。
  • c.470T>C/p.I157T与NMTC的OR在各组为1.75、1.52和2.31,95%CI均跨1。

核心结论

  • 对非选择性NMTC患者的分析提示,CHEK2变异c.1100del和c.470T>C/p.I157T对甲状腺癌风险仅有 modest 影响。
  • 这些结果为临床提供者提供了关于这些CHEK2变异相关甲状腺癌风险相对较低幅度的重要信息。

研究设计与样本

  • 病例对照研究设计,在三个非选择性NMTC患者组中评估三种CHEK2奠基者变异(c.444+1G>A、c.1100del、c.470T>C/p.Ile157Thr)。
  • 第一组为既往已发表全基因组关联分析(GWAS)中的1544例NMTC患者和1593例对照。
  • 第二组为789例接受胚系外显子测序的NMTC患者(Oncology Research Information Exchange Network [ORIEN] Avatar)。
  • 第三组为癌症基因组图谱(TCGA)中499例具有胚系序列数据的NMTC患者。
  • 计算OR时均与俄亥俄州立大学GWAS对照组比较。

主要发现

  • 波兰主要变异c.444+1G>A仅见于1例。
  • c.1100del在GWAS组、ORIEN Avatar组和TCGA组的比例分别为0.92%、1.65%和0.80%。
  • c.1100del与NMTC的OR(95%CI)分别为1.71(0.73-4.29)、2.64(0.95-7.63)和2.5(0.63-8.46)。
  • c.470T>C/p.I157T在GWAS组、ORIEN Avatar组和TCGA组的比例分别为0.91%、0.76%和0.80%。
  • c.470T>C/p.I157T与NMTC的OR(95%CI)分别为1.75(0.74-4.39)、1.52(0.42-4.96)和2.31(0.58-7.90)。

临床怎么用

  • 作者认为,这些结果可为临床提供者提供关于c.1100del和c.470T>C/p.I157T相关甲状腺癌风险相对较低幅度的信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Germline pathogenic variants in CHEK2 are associated with a moderate increase in the lifetime risk for breast cancer. Increased risk for other cancers, including non-medullary thyroid cancer (NMTC), has also been suggested. To date, data implicating CHEK2 variants in NMTC predisposition primarily derive from studies within Poland, driven by a splice site variant (c.444 + 1G>A) that is uncommon in other populations. In contrast, the predominant CHEK2 variants in non-Polish populations are c.1100del and c.470T>C/p.I157T, representing 61.1% and 63.8%, respectively, of all CHEK2 pathogenic variants in two large U.S.-based commercial laboratory datasets. To further delineate the impact of common CHEK2 variants on thyroid cancer, we aimed to investigate the association of three CHEK2 founder variants (c.444 + 1G>A, c.1100del, and c.470T>C/p.Ile157Thr) on NMTC susceptibility in three groups of unselected NMTC patients. Methods: The presence of three CHEK2 founder variants was assessed within three groups: (1) 1544 NMTC patients (and 1593 controls) from previously published genome-wide association study (GWAS) analyses, (2) 789 NMTC patients with germline exome sequencing (Oncology Research Information Exchange Network [ORIEN] Avatar), and (3) 499 NMTC patients with germline sequence data available in The Cancer Genome Atlas (TCGA). A case-control study design was utilized with odds ratios (ORs) calculated by comparison of all three groups with the Ohio State University GWAS control group. Results: The predominant Polish variant (c.444 + 1G>A) was present in only one case. The proportion of patients with c.1100del was 0.92% in the GWAS group, 1.65% in the ORIEN Avatar group, and 0.80% in the TCGA group. The ORs (with 95% confidence intervals [CIs]) for NMTC associated with c.1100del were 1.71 (0.73-4.29), 2.64 (0.95-7.63), and 2.5 (0.63-8.46), respectively. The proportion of patients with c.470T>C/p.I157T was 0.91% in the GWAS group, 0.76% in the ORIEN Avatar group, and 0.80% in the TCGA group, respectively. The ORs (with CIs) for NMTC associated with c.470T>C/p.I157T were 1.75 (0.74-4.39), 1.52 (0.42-4.96), and 2.31 (0.58-7.90), respectively. Conclusions: Our analyses of unselected patients with NMTC suggest that CHEK2 variants c.1100del and c.470T>C/p.I157T have only a modest impact on thyroid cancer risk. These results provide important information for providers regarding the relatively low magnitude of thyroid cancer risk associated with these CHEK2 variants.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Brock P, Liynarachchi S, Nieminen TT, et al. CHEK2 Founder Variants and Thyroid Cancer Risk. Thyroid. 2024. PMID: 38279823. doi:10.1089/thy.2023.0529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。